LIPID PROFILE IN HYPERTENSIVE PATIENTS TREATED WITH LIPID LOWERING THERAPY: PP.23.446

Abstract

Objectives: Some studies show that low levels of HDL cholesterol and high levels of triglycerides (TG) have a negative impact on cardiovascular morbidity-mortality and may contribute to residual cardiovascular risk (CVR) in patients treated with statins, whose main target is to reduce the levels of low-density lipoproteins (LDL). The objective of this study was to estimate the prevalence of alterations in the lipid profile and their relationship with other CVR factors in hypertensive and dyslipemic patients receiving lipid lowering treatment. Methods: This was observational and cross-sectional. As inclusion criteria, hypertensive patients had to be treated with lipid lowering agents (statins, fibrates, ezetimibe) and have a lipid profile with lipoproteins made in the 3 previous months, with a clinical and biological assessment with stratification of the CVR. Lipid control was determined basing on ATP-III. According to the alterations in the lipid profile, patients were classified in 4 groups: G1 (no lipid alterations); G2 (LDL-C increased, normal HDL-C and TG); G3 (LDL-C increased and low HDL-C and/or high TG); G4, (normal LDL-C with low HDL-C and/or high TG). Results: Out of 3216 patients (52.1 women, mean age 63.9 years-old), 40.8% did not achieve the LDL-C. Almost 31.4% of patients was in group 1, 22.6% in group 2, 18.2% in group 3 and 27.8% in group 4. High levels of TG and/or low levels of HDL-C were more associated with other CVR factors (obesity, diabetes, smoking habit and high blood pressure (BP) values; p < 0.001). On the contrary, this association was not present in patients with high levels of LDL-C, except if smokers patients (p < 0.001). Conclusions: In hypertensive patients with dyslipidemia treated with lipid lowering therapy, the prevalence of alterations in the lipid profile is a quite usual disorder, especially with regards to high levels of triglycerides and low levels of HDL-C which are not usually considered therapeutic targets; this helps maintain a residual cardiovascular risk in these patients, despite the treatment.